Filing Analysis
Allurion Technologies was notified by the NYSE on March 6, 2026, that the exchange will commence delisting proceedings and has suspended trading of its common stock and warrants. The delisting is due to the company's failure to maintain an average global market capitalization of at least $15 million over a 30-day period.
Red Flags
- Market capitalization has fallen below the $15 million threshold, indicating extreme financial distress.
- Immediate suspension of trading on the NYSE.
- Transition to OTCID Market typically results in significantly lower liquidity and higher volatility.
- Warrants are extremely out-of-the-money with an exercise price of $202.50.
Key Facts
- NYSE notified the company of delisting proceedings on March 6, 2026, due to non-compliance with Rule 802.01B.
- Average global market capitalization fell below $15 million over a 30 consecutive trading day period.
- Trading in Common Stock (ALUR) and Warrants (ALUR.WS) was suspended after market close on March 6, 2026.
- The company's securities are currently trading on the OTCID Market while an appeal is pending.
- Warrants have an exercise price of $202.50 per share of Common Stock.
- The company recently received FDA approval for the Allurion Gastric Balloon System.
Allurion Technologies received a formal delisting notice from the NYSE on March 2, 2026, after failing to meet the minimum $50 million stockholders' equity or market capitalization requirements. The NYSE will commence delisting proceedings, although the company intends to appeal the determination to maintain its listing status temporarily.
Red Flags
- Commencement of formal delisting proceedings by the NYSE.
- Prolonged non-compliance with listing standards dating back to August 2024.
- Market capitalization and stockholders' equity have fallen below the $50 million threshold.
- Heavy reliance on debt-to-equity restructuring and capital raising to attempt compliance.
Key Facts
- Delisting notice received from NYSE on March 2, 2026, regarding Section 802.01B compliance.
- Company failed to maintain at least $50 million in stockholders' equity or a 30-trading day average market capitalization of $50 million.
- The company was previously notified of non-compliance on August 29, 2024.
- Allurion intends to appeal the NYSE's determination and request a review by a Committee of the Board of Directors of the Exchange.
- The company recently completed a warrant inducement transaction on February 24, 2026, and is negotiating a debt-for-preferred-stock exchange with its largest creditor.
Allurion Technologies entered into a warrant exercise inducement agreement to raise approximately $3.0 million in gross proceeds by significantly lowering the exercise price of existing warrants. In exchange for exercising 2.66 million warrants at the reduced price of $1.15, the company issued 5.32 million new warrants to the participating holders.
Red Flags
- Significant downward repricing of existing warrants (from $6.00/$5.23 to $1.15) indicates a lack of leverage and potential distress.
- Highly dilutive structure involving the issuance of two new warrants for every one warrant exercised.
- The relatively small capital raise ($3.0 million) suggests an urgent need for liquidity.
- Multiple 8-K items triggered (1.01, 3.02, 3.03) reflecting material modifications to security holder rights.
Key Facts
- Existing warrants from January, February, and November 2025 had exercise prices reduced from as high as $6.00 to $1.15 per share.
- Exercising holders agreed to purchase 2,659,565 shares of common stock for cash.
- The company issued 5,319,130 new warrants (a 2-for-1 ratio relative to exercised warrants) with an exercise price of $1.15 and a five-year term.
- Total gross proceeds from the transaction are approximately $3.0 million.
- Roth Capital Partners acted as financial advisor, receiving a 5.0% fee on gross proceeds.
Allurion Technologies (ALUR) filed an 8-K under Item 7.01 (Regulation FD) on February 23, 2026, announcing that the FDA granted Pre-Market Approval (PMA) for its Allurion Gastric Balloon System featuring the Allurion Smart Capsule, targeting adults with obesity (BMI 30–40 kg/m²) aged 22–65 who have failed at least one prior weight loss program. While this represents a significant positive regulatory milestone for the company, the filing simultaneously contains explicit going concern language and references to the company's need for additional financing to support commercialization.
Red Flags
- Explicit going concern language in forward-looking statements: 'the ability of the Company to obtain sufficient financing to continue as a going concern'
- Capital raising uncertainty acknowledged: risk that capital raising process 'will not result in the Company pursuing any transactions or that any transaction, if pursued, will be completed on attractive terms or at all'
- PMA approval does not guarantee successful commercialization — company explicitly flags risk of inability to 'maintain FDA approval' and 'commercialize the Allurion Smart Capsule'
- Warrant exercise price of $202.50 per share vs. micro-cap profile suggests significant prior stock price deterioration and potential dilution overhang
- 10-K was amended in August 2025, potentially indicating post-filing corrections or material updates
Key Facts
- FDA granted PMA (Pre-Market Approval) for the Allurion Gastric Balloon System featuring the Allurion Smart Capsule on February 23, 2026
- Indicated for adults with obesity aged 22–65 with BMI ≥ 30 kg/m² and ≤ 40 kg/m² who have had at least one unsuccessful weight loss attempt
- Filing made under Item 7.01 (Regulation FD); press release attached as Exhibit 99.1
- Forward-looking statements reference the company's ability to 'obtain sufficient financing to continue as a going concern'
- Company acknowledges risk that 'capital raising process will not result in the Company pursuing any transactions or that any transaction, if pursued, will be completed on attractive terms or at all'
- Company is classified as an Emerging Growth Company (EGC)
- Common stock (ALUR) and warrants (ALUR WS) listed on the New York Stock Exchange
- Warrant terms reference exercise price of $202.50 per share for 0.056818 shares of common stock
- Filing signed by Brendan M. Gibbons, Chief Legal and People Officer
- Most recent 10-K filed March 27, 2025 (amended August 19, 2025); most recent 10-Q filed November 17, 2025